Revenue target of ₹1,000 Cr
Long-term target reiterated; may slip by 5-6 months from original FY28 timeline.
LINCOLNPHARMACEUTICALS / guidance tracker
Keep management guidance in view.
Lincoln Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin guidance of 15-18%
Management expects EBITDA margin to remain in 15-18% range; 15% is the floor.
CIFA block revenue target of ₹90-120 Cr in FY27
CIFA block expected to reach ₹90-120 Cr revenue next year (from ~₹45 Cr in FY26).
R&D spend to increase to 3-3.25% of sales
R&D expenses to rise from current 1.8-2% to 3-3.25% to support regulated market filings.